Serum C terminal telopeptide maintains its correlation with bone disease in patients with myeloma even under treatment with bisphosphonates

Leuk Lymphoma. 2014 Jun;55(6):1397-8. doi: 10.3109/10428194.2013.830305. Epub 2013 Sep 3.
No abstract available

Publication types

  • Letter

MeSH terms

  • Bone Density Conservation Agents / therapeutic use
  • Bone Diseases / etiology*
  • Collagen Type I / blood*
  • Diphosphonates / therapeutic use
  • Humans
  • Multiple Myeloma / blood*
  • Multiple Myeloma / complications*
  • Multiple Myeloma / drug therapy
  • Peptides / blood*

Substances

  • Bone Density Conservation Agents
  • Collagen Type I
  • Diphosphonates
  • Peptides
  • collagen type I trimeric cross-linked peptide